HomeCompareDRRX vs PLD

DRRX vs PLD: Dividend Comparison 2026

DRRX yields 104.71% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $1.79M in total portfolio value· pulled ahead in Year 10
10 years
DRRX
DRRX
● Live price
104.71%
Share price
$1.91
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.71M
Annual income
$1,637,812.78
Full DRRX calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — DRRX vs PLD

📍 PLD pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDRRXPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DRRX + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DRRX pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DRRX
Annual income on $10K today (after 15% tax)
$8,900.52/yr
After 10yr DRIP, annual income (after tax)
$1,392,140.86/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, PLD beats the other by $3,075,829.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DRRX + PLD for your $10,000?

DRRX: 50%PLD: 50%
100% PLD50/50100% DRRX
Portfolio after 10yr
$5.61M
Annual income
$3,447,124.48/yr
Blended yield
61.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

DRRX
Analyst Ratings
8
Buy
5
Hold
Consensus: Buy
Altman Z
-67.3
Piotroski
2/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DRRX buys
0
PLD buys
0
No recent congressional trades found for DRRX or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDRRXPLD
Forward yield104.71%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$4.71M$6.50M
Annual income after 10y$1,637,812.78$5,256,436.18
Total dividends collected$4.23M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: DRRX vs PLD ($10,000, DRIP)

YearDRRX PortfolioDRRX Income/yrPLD PortfolioPLD Income/yrGap
1$21,171$10,471.20$11,255$555.24+$9.9KDRRX
2$43,372$20,718.50$13,062$1,018.59+$30.3KDRRX
3$86,075$39,667.56$15,903$1,926.67+$70.2KDRRX
4$165,674$73,573.88$20,839$3,823.32+$144.8KDRRX
5$309,620$132,347.88$30,464$8,166.08+$279.2KDRRX
6$562,449$231,156.47$52,054$19,457.30+$510.4KDRRX
7$994,265$392,443.71$109,886$54,188.93+$884.4KDRRX
8$1,712,217$648,353.89$304,030$186,451.18+$1.41MDRRX
9$2,875,555$1,043,482.55$1,166,125$840,813.32+$1.71MDRRX
10← crossover$4,714,656$1,637,812.78$6,504,190$5,256,436.18$1.79MPLD

DRRX vs PLD: Complete Analysis 2026

DRRXStock

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Full DRRX Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this DRRX vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DRRX vs SCHDDRRX vs JEPIDRRX vs ODRRX vs KODRRX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.